Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade
Protein phosphatase 2A (PP2A) has been proposed as a target for cancer immunotherapy. Here the authors show that pharmacological inhibition of PP2A with a clinically-relevant inhibitor enhances response to immune checkpoint blockade in pre-clinical models of cancer, resulting in long lasting immunit...
Guardado en:
Autores principales: | Winson S. Ho, Herui Wang, Dominic Maggio, John S. Kovach, Qi Zhang, Qi Song, Francesco M. Marincola, John D. Heiss, Mark R. Gilbert, Rongze Lu, Zhengping Zhuang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fa23d329feb04210ba229907d41699e4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma
por: Elena Galvani, et al.
Publicado: (2020) -
LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade
por: Yi Liu, et al.
Publicado: (2021) -
Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance
por: Yong Liang, et al.
Publicado: (2018) -
Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity
por: Shahram Salek-Ardakani, et al.
Publicado: (2021) -
Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea M, et al.
Publicado: (2021)